Pfizer 'breakthrough' meningitis B vaccine OK'd; beats Novartis
This article was originally published in Scrip
Executive Summary
The FDA on 29 October granted an accelerated approval to Pfizer's Trumenba (meningococcal group B vaccine) for active immunization in people 10-25 years to prevent invasive disease caused by Neisseria meningitidis serogroup B, which can be life-threatening.